RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3...
RXi Pharmaceuticals (RXII +16%) pops after the firm gives a positive update on its phase 3 clinical trial of NeuVax, a cancer immunotherapy targeted for breast cancer patients not eligible for other treatment.
From other sites
at Zacks.com (Apr 9, 2015)
at Zacks.com (Mar 18, 2015)
at Zacks.com (Mar 9, 2015)
at CNBC.com (May 21, 2014)
at CNBC.com (Apr 8, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs